BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7378577)

  • 1. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.
    Merlini G; Waldenström JG; Jayakar SD
    Blood; 1980 Jun; 55(6):1011-9. PubMed ID: 7378577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
    Pasqualetti P; Casale R; Colantonio D; Festuccia V; Di Lauro G; Natali G
    Minerva Med; 1987 May; 78(9):603-8. PubMed ID: 3587727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the staging system proposed by Merlini, Waldenström and Jayakar for multiple myeloma.
    Bettini R; Steidl L; Rapazzini P; Giardina G
    Acta Haematol; 1983; 70(6):379-85. PubMed ID: 6417962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosynthesis of immunoglobulin in human immunoproliferative diseases. II. Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with that calculated from clinical staging systems.
    Cooper DA; Miller AC; Penny R
    Acta Haematol; 1982; 68(3):224-36. PubMed ID: 6814151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.
    Durie BG; Salmon SE; Moon TE
    Blood; 1980 Mar; 55(3):364-72. PubMed ID: 7357075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
    Durie BG; Salmon SE
    Cancer; 1975 Sep; 36(3):842-54. PubMed ID: 1182674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in IgD myeloma: a study of 21 cases.
    Fibbe WE; Jansen J
    Scand J Haematol; 1984 Nov; 33(5):471-5. PubMed ID: 6515330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor.
    Symeonidis A; Kouraklis-Symeonidis A; Grouzi E; Zolota V; Melachrinou M; Kourea K; Fragopanagou E; Giannakoulas N; Seimeni U; Tiniakou M; Matsouka P; Zoumbos N
    Leuk Lymphoma; 2002 Aug; 43(8):1605-12. PubMed ID: 12400603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic variables and clinical staging in multiple myeloma.
    Cavo M; Galieni P; Zuffa E; Baccarani M; Gobbi M; Tura S
    Blood; 1989 Oct; 74(5):1774-80. PubMed ID: 2790201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of abnormal immunoglobulin with clinical features of myeloma.
    Arch Intern Med; 1975 Jan; 135(1):46-52. PubMed ID: 1111470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
    San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
    Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloma.
    Ameér L
    Acta Med Scand; 1976; 199(6):543-4. PubMed ID: 937083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features.
    Pasqualetti P; Casale R; Collacciani A; Colantonio D
    Eur J Cancer; 1991; 27(9):1123-6. PubMed ID: 1835621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
    Pasqualetti P; Colantonio D; Casale R; Lorenzetti G; Natali G
    Recenti Prog Med; 1989 Oct; 80(10):543-6. PubMed ID: 2602637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homogeneous immunoglobulins in Ghanaians living in Accra, Ghana.
    Oyeyinka GO; Ofei V; Maddy SQ; Duah OA; Akafo SK; Aquaye JK; Dosoo DK
    Afr J Med Med Sci; 2004 Dec; 33(4):311-6. PubMed ID: 15977437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reappraisal of plateau phase in myeloma.
    Durie BG; Russell DH; Salmon SE
    Lancet; 1980 Jul; 2(8185):65-8. PubMed ID: 6105246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
    Rapoport BL; Falkson HC; Falkson G
    S Afr Med J; 1991 Jan; 79(2):65-7. PubMed ID: 1989088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
    Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case report of multiple myeloma with marked Bence Jones proteinuria but slight serum mono component (IgG-kappa), showing lymphoid plasma cells in the bone marrow].
    Hishitani Y; Shinoda K; Yasui T; Mozai T; Kanoh T; Yasuda N
    Rinsho Ketsueki; 1984 Nov; 25(11):1831-6. PubMed ID: 6442739
    [No Abstract]   [Full Text] [Related]  

  • 20. Biclonal gammopathy in multiple myeloma: a case report.
    Bakta IM; Sutarka IN
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():544-8. PubMed ID: 10895208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.